How much did Dexcom achieve in EBIT for the current year?
In the current year, Dexcom has achieved an EBIT of 901.11 M USD.
Dexcom EBIT 2024
Dexcom EBIT
901.11 M USD
Dexcom Dividend yield
Ticker
DXCM
ISIN
US2521311074
WKN
A0D9T1
In 2024, Dexcom's EBIT was 901.11 M USD, a 46.69% increase from the 614.3 M USD EBIT recorded in the previous year.
The Dexcom EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | 2.04 |
| 2027e | 1.72 |
| 2026e | 1.46 |
| 2025e | 1.16 |
| 2024e | 0.9 |
| 2023 | 0.61 |
| 2022 | 0.41 |
| 2021 | 0.29 |
| 2020 | 0.32 |
| 2019 | 0.16 |
| 2018 | -0.19 |
| 2017 | -0.04 |
| 2016 | -0.06 |
| 2015 | -0.06 |
| 2014 | -0.02 |
| 2013 | -0.03 |
| 2012 | -0.06 |
| 2011 | -0.04 |
| 2010 | -0.05 |
| 2009 | -0.05 |
| 2008 | -0.05 |
| 2007 | -0.05 |
| 2006 | -0.05 |
| 2005 | -0.03 |
| 2004 | -0.01 |
Dexcom Aktienanalyse
What does Dexcom do?
Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Dexcom's EBIT
Dexcom's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Dexcom's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Dexcom's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Dexcom’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Dexcom Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Dexcom.
How has the EBIT of Dexcom developed in recent years?
The EBIT of Dexcom has increased by 46.689% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Dexcom?
The EBIT of Dexcom is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Dexcom pay?
Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.
What is the dividend yield of Dexcom?
The current dividend yield of Dexcom is .
When does Dexcom pay dividends?
Dexcom pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Dexcom?
Dexcom paid dividends every year for the past 0 years.
What is the dividend of Dexcom?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Dexcom located?
Dexcom is assigned to the 'Health' sector.
Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dexcom from 6/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/8/2024.
When did Dexcom pay the last dividend?
The last dividend was paid out on 6/8/2024.
What was the dividend of Dexcom in the year 2023?
In the year 2023, Dexcom distributed 0 USD as dividends.
In which currency does Dexcom pay out the dividend?
The dividends of Dexcom are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Dexcom stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Dexcom
Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
